LAVA Therapeutics at Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 — LAVA Therapeutics N.V. (NASDAQ: LVTX), a clinical-stage company in the field of immuno-oncology, announced that its President and CEO, Stephen Hurly, will be participating in a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for Wednesday, June 5, 2024, at 8:00 a.m. ET. The live webcast of this discussion will be accessible through the "Events" section on the LAVA Therapeutics website, where it will remain archived for 90 days post-presentation.

LAVA Therapeutics specializes in developing bispecific gamma-delta (δ2) T cell engagers through its proprietary Gammabody® platform. The company aims to create therapies for both solid tumors and hematologic malignancies by leveraging these engineered antibodies. These antibodies are designed to precisely target and kill cancer cells by activating Vγ9Vδ2 T cell effector functions when they bind to tumor-associated antigens.

The company's key program, LAVA-1207, is currently in a Phase 1/2a dose escalation trial (NCT05369000) for metastatic castration-resistant prostate cancer (mCRPC). This trial is taking place in both Europe and the United States and includes testing LAVA-1207 as a monotherapy and in combination with interleukin-2 (IL-2). Additionally, LAVA Therapeutics is expanding the Phase 1/2a study to explore a combination treatment with KEYTRUDA® (pembrolizumab), in collaboration with Merck & Co., Inc., Rahway, NJ, USA.

Moreover, LAVA Therapeutics has licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for its clinical development and commercialization. Apart from these, the company has a number of pre-clinical programs in its pipeline, aiming to further advance the field of immuno-oncology.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. LLC, based in Rahway, NJ, USA. Gammabody® is a registered trademark of LAVA Therapeutics N.V.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!